In memory
Steve Jobs and a Rare Kind of Pancreatic Cancer
Apple co-founder Steve Jobs had a pancreatic neuroendocrine tumor — a less common form of pancreatic cancer. Here's what that means, from the National Cancer Institute.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
On screen
Steve Jobs, the co-founder of Apple, was diagnosed in 2003 with a tumor in the islet cells of his pancreas — what has been widely reported as a pancreatic neuroendocrine tumor. This is a less common form of pancreatic cancer than the type most people picture. He underwent treatment over the following years and died on October 5, 2011, at the age of 56. His diagnosis drew attention in part because it highlighted an important distinction: "pancreatic cancer" is not a single disease.
His story offers a chance to understand that the pancreas can give rise to more than one kind of cancer, and that the type matters a great deal.
The reality
According to the National Cancer Institute, pancreatic cancer can develop from two kinds of cells in the pancreas: exocrine cells and neuroendocrine cells, such as islet cells. NCI explains that the exocrine type is more common and is usually found at an advanced stage. Pancreatic neuroendocrine tumors — also called islet cell tumors — are less common but, as NCI notes, have a better prognosis. From NCI's broader material, neuroendocrine tumors form from cells that release hormones into the blood in response to signals from the nervous system, and they may be benign or malignant. This difference in cell type is central to understanding why Jobs's cancer was described differently from the more familiar form.
What the story gets right — and what to remember
The most useful lesson from Jobs's story is that the word "pancreatic cancer" covers more than one disease, and the specific type shapes what to expect. His experience is one person's history, and outcomes vary enormously from case to case. Public reporting on a well-known figure is not a substitute for individual medical guidance, and every diagnosis is different. The takeaway is understanding, not comparison.
Awareness, screening & prevention
Here NCI is refreshingly direct about the limits of current knowledge. NCI states that it does not have evidence-based information about screening for pancreatic cancer, and likewise does not have evidence-based information about prevention of pancreatic cancer. In other words, there is no standard screening test for the general population. NCI points instead to its general resources on cancer screening and prevention. A reasonable general takeaway is to discuss any persistent or unexplained symptoms with a healthcare professional.
Turning a story into something useful
Steve Jobs's name is tied to invention — and his diagnosis quietly taught many people that cancers of the same organ can be very different diseases. Honoring that can mean learning those distinctions, asking good questions, and understanding that reliable information matters more than assumptions. Supporting free cancer education helps others learn these facts too.
Questions to ask a healthcare team
- What is the difference between exocrine pancreatic cancer and a pancreatic neuroendocrine tumor?
- Why does the specific cell type of a cancer matter for treatment and outlook?
- Are there standard screening tests for pancreatic cancer, and why or why not?
- What symptoms related to the pancreas or digestion are worth discussing?